title: Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD.
abstract: Stimulant medication and behavioral treatments are evidence-based for children with attention-deficit/hyperactivity disorder, but the combination of the 2 treatments has been understudied. In this investigation, methylphenidate (MPH) was crossed with 2 levels of behavior modification (BMOD) in a summer treatment program. Twenty-seven children with attention-deficit/hyperactivity disorder, aged 6-12, participated. Children received placebo and 3 doses of transdermal MPH (12.5 cm(2), 25.0 cm(2), and 37.5 cm(2)). BMOD was implemented on alternating weeks. Both treatments produced large and significant effects. Combined treatment was superior to either treatment alone. The effects of transdermal MPH were comparable to those found in this setting in previous studies with multiple stimulant medications and formulations. Consistent with other research, low doses of MPH--even lower than in previous studies--yielded enhanced effects in combination with behavior modification.
authors.affiliation: Department of Psychology, University at Buffalo, State University of New York, 14214, USA. pelham@buffalo.edu
authors.forename: William E
authors.initials: WE
authors.lastname: Pelham
authors.forename: Lisa
authors.initials: L
authors.lastname: Burrows-Maclean
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Gnagy
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Fabiano
authors.forename: Erika K
authors.initials: EK
authors.lastname: Coles
authors.forename: Katy E
authors.initials: KE
authors.lastname: Tresco
authors.forename: Anil
authors.initials: A
authors.lastname: Chacko
authors.forename: Brian T
authors.initials: BT
authors.lastname: Wymbs
authors.forename: Amber L
authors.initials: AL
authors.lastname: Wienke
authors.forename: Kathryn S
authors.initials: KS
authors.lastname: Walker
authors.forename: Martin T
authors.initials: MT
authors.lastname: Hoffman
mesh_terms: D000279:Administration, Cutaneous; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology / Q000628:therapy*; D001519:Behavior; D001521:Behavior Therapy; D000697:Central Nervous System Stimulants / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D013315:Stress, Psychological / Q000523:psychology; D016896:Treatment Outcome
chemical_list: D000697:Central Nervous System Stimulants; D008774:Methylphenidate